Big Value Deals for Small Market Drugs?
Surprisingly, specialist products, though generally for smaller markets, have been averaging higher deal values than those for primary care over the past three years.
You may also be interested in...
Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.